A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients.
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2011
At a glance
- Drugs BMS 275183 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 22 Feb 2007 Status changed from in progress to discontinued.
- 02 Feb 2007 Status changed from recruiting to in progress.
- 07 Nov 2006 New trial record.